Related Experiment Videos
ApoE phenotype influences plasma ASP in hyperapoB subjects
Katherine Cianflone1, Steve Phélis, Jean Davignon
1Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, H7.30, 687 Pine Ave West, Quebec, Montreal, Canada H3A 1A1. katherine.cianflone@mcgill.ca
Atherosclerosis
|November 13, 2003
Summary
Acylation stimulating protein (ASP) levels are elevated in cardiovascular patients with dyslipidemias. This study found that apolipoprotein E (apoE) phenotype, particularly rare variants like E2/2 and E4/4, influences ASP levels, especially in individuals with high apolipoprotein B.
Area of Science:
- Cardiovascular disease research
- Lipid metabolism and genetics
- Endocrinology and metabolic disorders
Background:
- Acylation stimulating protein (ASP) is implicated in lipid metabolism and is often elevated in cardiovascular patients experiencing dyslipidemias.
- The role of apolipoprotein E (apoE) phenotype in modulating ASP levels remains incompletely understood, particularly in the context of varying lipid profiles.
Purpose of the Study:
- To investigate the impact of apolipoprotein E (apoE) phenotype and plasma lipid levels on Acylation stimulating protein (ASP) concentrations.
- To determine if specific apoE genotypes are associated with altered ASP levels in individuals with and without hyperapolipoprotein B (HyperapoB).
Main Methods:
- Plasma levels of ASP, lipids (triglycerides, cholesterol, LDL cholesterol), apolipoprotein B (apoB), and apoE phenotype were measured in 407 subjects.
- Subjects were stratified into HyperapoB (HB) and normal apoB (NB) groups based on apoB levels (75th percentile).
- Statistical analyses, including ANOVA and stepwise regression, were used to assess relationships between variables.
Main Results:
- The HyperapoB (HB) group exhibited significantly higher triglyceride, cholesterol, LDL cholesterol, and ASP levels compared to the normal apoB (NB) group.
- In the NB group, ASP levels were not significantly different across common apoE3 variants but were elevated in rare E2/2 and E4/4 phenotypes.
- In the HB group, ASP levels were significantly increased in E2/4, E2/2, and E4/4 phenotypes, suggesting a strong influence of rare apoE variants.
- Stepwise regression identified plasma non-esterified fatty acid, triglyceride, and cholesterol as key predictors of ASP levels (r=0.407, P=0.001).
Conclusions:
- Apolipoprotein E (apoE) phenotype, particularly rare variants (E2/2, E4/4), can significantly influence Acylation stimulating protein (ASP) levels.
- The interplay between apoE phenotype and lipid profile, especially in HyperapoB individuals, is crucial for understanding ASP variations.
- These findings highlight a potential genetic component in ASP regulation, particularly within specific apoE genotypes and dyslipidemic conditions.